山东省卫生健康委：以组合拳护航医药产业创新升级

Core Viewpoint - The Shandong Provincial Government is implementing a comprehensive reform plan to enhance the regulation of pharmaceuticals and medical devices, aiming to promote high-quality development in the pharmaceutical industry, which is crucial for national economy and security [1][2]. Group 1: Policy Initiatives - The Shandong Provincial Health Commission will utilize a combination of policy guidance, service optimization, and regulatory assurance to inject new momentum into the high-quality development of the pharmaceutical industry [1]. - A dynamic linkage mechanism will be established between hospital drug supply and the medical insurance drug catalog, facilitating the clinical application of innovative drugs [1]. Group 2: Clinical Evaluation and Support - A comprehensive clinical evaluation system will be developed to assess the safety, efficacy, economic viability, innovation, suitability, and accessibility of drugs, particularly focusing on conditionally approved innovative drugs [2]. - Clinical trial support capabilities will be enhanced by incorporating clinical research into the evaluation of public hospitals' quality, allowing for dedicated beds for innovative drug trials not to count towards total bed numbers [2]. Group 3: Traditional Medicine and Collaboration - The "Qilu Traditional Chinese Medicine Brand Project" will be implemented to promote the quality and added value of traditional Chinese medicine, including the establishment of ecological planting bases for medicinal materials [2]. - A regular consultation mechanism will be established among the Health Commission, Medical Insurance Bureau, and Drug Administration to facilitate data sharing and address cross-sector issues related to innovative drug evaluation and clinical application [3].